Rivaroxaban showed similar results to warfarin in patients with atrial fibrillation and a bioprosthetic mitral valve for mean time to death, major cardiovascular events and major bleeding at 12 months, according to a study presented at the American Heart Association's virtual meeting and published in the New England Journal of Medicine. Dr. Donald Lloyd-Jones of Northwestern University commented that the study results could lead to broader use of rivaroxaban in patients with AF.
Rivaroxaban similar to warfarin in subset of AF patients
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.